What question did this study set out to answer?

The review aims to address the challenges of current immune checkpoint inhibitors and explore the potential of bispecific antibodies in treating metastatic non-small cell lung cancer.

February 25, 2026Open Access

Evolution of Immune Checkpoint Blockade in Metastatic NSCLC: A Narrative Review of Emerging Bispecific Antibodies and the Practical Challenges of Clinical Integration

Key Points

The review aims to address the challenges of current immune checkpoint inhibitors and explore the potential of bispecific antibodies in treating metastatic non-small cell lung cancer.
Analyzed landmark trials to establish the current standard of care
Evaluated emerging bispecific antibodies and their mechanisms
Discussed early-phase clinical studies for dual checkpoint blockers
Compared theoretical benefits of bispecific antibodies against conventional therapies
Bispecific antibodies show promise in improving pharmacokinetics and synergistic efficacy.
Key benefits include the potential for enhanced overall and progression-free survival.
Challenges include unclear survival benefits over established treatments and managing new toxicity profiles.

Abstract

Background/Objectives: Metastatic non-small cell lung cancer (mNSCLC) is challenged by toxicity, pharmacokinetic (PK) mismatch, and resistance inherent in current immune checkpoint inhibitor (ICI) regimens. Bispecific antibodies (BsAbs), which unify dual-target engagement within a single, structurally engineered molecule, offer a next-generation strategy to transcend these therapeutic ceilings. Their engineering formats—ranging from IgG-like full-size antibodies to non-IgG-like fragment-based or smaller scaffolds—are selected to further optimize target affinity and enhance therapeutic efficacy. Methods: This narrative review analyzes landmark trials establishing the current standard of care (SoC) and evaluates the mechanistic rationale and status of emerging BsAb, including dual checkpoint blockers and tumor microenvironment (TME)-modulating BsAbs, using the data from the latest early-phase clinical studies. Results: The review critically focuses on comparing the theoretical benefits of BsAbs, such as PK consistency and synergistic efficacy via affinity-controlled dual targeting, against the practical drawbacks of conventional combination therapies. Most importantly, it assesses the BsAbs’ potential to secure superior overall survival (OS) or progression-free survival (PFS) against established SoC and deeply reviews the clinical feasibility of managing their unique safety profiles. Conclusions: While BsAbs offer a potent, innovative approach to enhancing anti-tumor immunity, substantial hurdles remain for their widespread clinical integration. Key challenges include: (1) demonstrating clear survival benefits over high-efficacy SoCs in late-stage trials; (2) establishing guidelines for managing novel toxicity profiles; and (3) addressing logistical barriers related to complex manufacturing and high costs. Furthermore, the validation of predictive biomarkers is essential to guide the personalized application of BsAb-based immunotherapies.

Evolution of Immune Checkpoint Blockade in Metastatic NSCLC: A Narrative Review of Emerging Bispecific Antibodies and the Practical Challenges of Clinical Integration

Key Points

Abstract

Cite This Study

Also Consider

Also Consider